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ABSTRACT
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder, marked by insufficient production of
SMN protein, leading to motor neuron dysfunction. Although ubiquitously produced throughout the body, motor neurons
and muscle cells are selectively impacted by decreased SMN, which has been linked to impaired oxidative
phosphorylation causing altered metabolic function and exercise intolerance. Nusinersen, administered directly to the
central nervous (CNS), is an approved therapy that increases SMN protein in an effort to restore motor neuron function.
PURPOSE: To evaluate the impact of treatment on markers of exercise tolerance in children and adults treated with
nusinersen is not known. METHODS: Nusinersen treated ambulatory children and adults with SMA completed a maximal
cardiopulmonary exercise (CPX) test on a cycle ergometer at two visits 6 months apart. Oxygen uptake (VO2) at peak
exercise, oxygen uptake efficiency slope (OUES), and ventilatory equivalent for oxygen (VE/VO2) at peak exercise were
determined. Paired sample t-tests were used to evaluate change between visits. RESULTS: Nine ambulatory children and
adults with SMA (89% male) (mean age=32.4, range=13-57 years) were included. The average length of time participants
had received treatment was 1.05 years (range= 0.59 – 1.30 years). VO2 significantly increased from 13.49 ml•kg-1• min-1
to 16.52 ml•kg-1• min-1 (P = 0.03), OUES increased from 1324 to 1495 ml•min-1 O2/L• min-1,and VE/VO2 increased from
44.9 to 49.0 after 6-months. No significant differences were found in OUES or VE/VO2 after six months of treatment.(P<
0.05) CONCLUSION: These results show potential to mitigate exercise intolerance with nusinersen treatment in
individuals with SMA. VO2 was significantly improved, but an attenuated OUES and exaggerated hyperventilation
response, representative measures of efficiency, persists. As aerobic capacity reflects the integrative function of multiple
body systems, the improvement observed may be attributed to tissues not directly targeted by Nusinersen. Exercise
testing is a valuable method of assessing muscle oxygen kinetics and suggested mitochondrial dysfunction observed in
SMA. Combining exercise with drug therapies may further enhance benefits seen by treatment alone and developing
specific muscle-targeted therapies may be warranted.

